Page 134 - ESHRE2019
P. 134
Clinical trials with hiPSC derivatives Damaged corneas
Kohji Nishida. Osaka University
Plans to treat damaged corneas using sheets of tissue made from induced
pluripotent stem cells
0.05-millimetre-thick sheets of corneal cells in 4 patients
First treatment is planned to take place before the end of July-2019
PCC Stem Cells - ESHRE Vienna 2019
Clinical trials with hiPSC derivatives Cancer patients
Fate Therapeutics, in collaboration with University California San Diego (Dan Kaufman), developed first off-the-shelf immunotherapy from hiPSC (Natural Killer Cells)(FT500).
The FT500 clinical trial is a two-arm study with up to 64 patients for the treatment of advanced solid tumors.
PCC Stem Cells - ESHRE Vienna 2019
132
129
